Teva Pharmaceutical Industries Ltd.
(NYSE: TEVA)
|
8:00 PM UTC, 05/16/25 | |||
---|---|---|---|---|
Last: $16.94 | Change: +0.07 | %Change: +0.41% | Volume: 9,765,065 |
Open: | $ 17.12 | Volume: | 9,765,065 | |
---|---|---|---|---|
High: | $ 17.22 | Yield(%) | 0.00 | |
Low: | $ 16.75 | P/E Ratio (ttm): | n/a | |
Dividend ($): | 0.07 | Market Cap ($): | 19.33B | |
EPS ($) | -1.14 | Shares Out: | 1.15B |
% Price Change (last 4 weeks): | 23.59 |
---|---|
% Price Change (last 13 weeks): | 1.44 |
% Price Change (last 26 weeks): | 0.72 |
% Price Change (last 52 weeks): | 3.50 |
% Price Change (year to date): | -23.46 |
Return on Equity (%): | -25.45 |
---|---|
Return on Assets (%): | -3.96 |
Return on Invested Capital (%): | -5.33 |
Gross Profit Margin (%): | 48.63 |
---|---|
Net Profit Margin (%): | -9.93 |
Operating Profit Margin (%): | 20.16 |
|
|
50-day Moving Average: | $15.45 |
---|---|
200-day Moving Average: | $17.54 |
Avg. Daily Vol. (last 50 days): | 12,703,321 |
Avg. Daily Vol. (last 200 days): | 10,335,830 |
52-wk high: | $22.80 |
52-wk low: | $12.46 |
Bid: | $16.71 |
Ask: | $17.01 |
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
|
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a Street Tel Aviv TA 6944020 Phone: 972.3.914.8213 Fax: n/a http://www.tevapharm.com |
Earnings (1year) ($): | -1.14 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 4.74 |
Cash Flow ($): | -0.51 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 1.51 |
Price/Book (x): | 4.65 |
Price/Cash Flow (x): | 9.82 |
Quick Ratio (x): | 0.75 |
---|---|
Current Ratio (x): | 0.98 |
LT Debt/Equity (x): | 303.33 |
Total Debt/Equity (x): | 338.10 |